Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434555 | 1.00 | LMNA (0.50) | LMNATSHRF2TDP1KMT2A | |
| SCHEMBL170291 | 0.90 | ESR1 (0.42) | LMNATSHRTDP1KMT2AMAPK1 | |
| SCHEMBL21528207 | 0.89 | LMNA (0.47) | LMNATSHRF2TDP1KMT2A | |
| SCHEMBL21528208 | 0.89 | LMNA (0.47) | LMNATSHRF2TDP1KMT2A | |
| SCHEMBL5133702 | 0.87 | LOXL2 (0.40) | LMNATSHRMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9175278 | 0.87 | ALDH1A1 (0.50) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL20503264 | 0.86 | LMNA (0.51) | LMNATSHRF2TDP1KMT2A | |
| SCHEMBL20503355 | 0.86 | LMNA (0.51) | LMNATSHRF2TDP1KMT2A | |
| SCHEMBL6293503 | 0.83 | TSHR (0.52) | LMNATSHRTDP1KMT2AMAPK1 | |
| SCHEMBL17459752 | 0.83 | LMNA (0.48) | LMNATSHRF2TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9279085-B2 | Method for the production of monofunctionalized dialkylphosphinic acids, esters and salts, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2016-03-08 | — | — | US | claimed |
| US-8735476-B2 | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ester of a carboxylic acid and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-05-27 | — | — | US | claimed |
| EP-2373667-B1 | METHOD FOR PRODUCING MONO-CARBOXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ESTER OF A CARBOXYLIC ACID AND THE USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-12-11 | — | — | EP | claimed |
| US-20110237721-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ester of a Carboxylic Acid and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-29 | — | — | US | claimed |
| US-9279085-B2 | Method for the production of monofunctionalized dialkylphosphinic acids, esters and salts, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2016-03-08 | — | — | US | disclosed |
| US-8735476-B2 | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ester of a carboxylic acid and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-05-27 | — | — | US | disclosed |
| US-20110251315-A1 | Method for the Production of Monofunctionalized Dialkylphosphinic Acids, Esters and Salts, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-13 | — | — | US | disclosed |
| US-20110237721-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ester of a Carboxylic Acid and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237721-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ester of a Carboxylic Acid and the Use Thereof | SCO2, HAO2, DAO | LMNA 2720/4885TSHR 1600/4885F2 502/4885 |
| US-20110251315-A1 | Method for the Production of Monofunctionalized Dialkylphosphinic Acids, Esters and Salts, and Use Thereof | LPAR6, LPAR2, HAO2 | LMNA 3960/4885TSHR 83/4885F2 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.